GENE ONLINE|News &
Opinion
Blog

2021-09-02| Asia-Pacific

South Korea’s Boryung Launches Avastin Biosimilar Developed by Samsung Bioepis

by Kathy Huang
Share To

On September 1, South Korea’s Boryung Pharmaceutical announced the launch of Onbevzi, a biosimilar of Roche’s blockbuster cancer drug Avastin (bevacizumab). Onbevzi was developed by Samsung Bioepis and won approval from the European Medicines Agency (EMA) last August.

Boryung acquired exclusive sales rights in Korea for the drug from its developer earlier this May. 

According to data compiled from IQVIA, a data sciences company, Avastin sold over 120 billion KRW in Korea in 2020. Therefore, it is conceivable the market potential of the drug attracted South Korea’s biggest anticancer drugs manufacturer Boryung to plunge in.

Related Article: Addressing The Global Need for Biosimilars: Current Trends, Expectations, and Real-World Experiences

 

What Is Avastin?

Avastin is a monoclonal antibody developed by Roche. Unlike chemotherapy which attacks cancer cells directly, Avastin strikes the cancer cells from another angle.

The drug blocks the vascular endothelial growth factor A (VEGF-A), a protein that is produced in excess by cancer cells. VEGF-A promotes the formation of new blood vessels that supply cancer cells with oxygen and nutrients. By reducing VEGF-A activity, slows down the growth of new blood vessels in patients and therefore prevents tumor progression. 

Avastin is used to treat non-small cell lung cancer, advanced breast cancer, kidney cancer, and bowel cancer. The drug can also be combined with chemotherapy.

 

Onbevzi’s Advantages over Avastin 

Onbevzi’s indications include metastatic colorectal cancer, breast cancer, non-small cell lung cancer, and epithelial ovarian cancer. The indications for Onbevzi overlap with those for Avastin.  

What makes Onbevzi unique is its low price: it is 37% cheaper than Avastin. According to Boryung, the competitiveness in its drug price and the enhanced ease of use will quickly expand its market share in Korea.    

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Kyowa Kirin’s Strategic Partner Sandoz KK Receives Nod for Rituximab Biosimilar
2023-10-03
GeneOnline’s Weekly News Highlights: Sept 11-Sept 15
2023-09-19
Novartis’ Generic-drugs Unit Partners with Samsung Bioepis for Biosimilar Drug Launch
2023-09-12
LATEST
BIODND – An AI-Powered Database That Breaks New Ground in Life Science Business Development
2023-11-29
GeneOnline’s Weekly News Highlights: Nov 20-Nov 24
2023-11-27
SK Bioscience and Hilleman Laboratories Join Forces for Ebola Vaccine Development
2023-11-23
BeiGene to Expand Oncology Pipeline Through ENSEM Therapeutics Partnership
2023-11-23
Advancing the Frontiers of Cell and Gene Therapy – An Interview with Dr. Shin Kawamata
2023-11-21
Astellas and Pfizer’s Drug Receives FDA Approval as Treatment for High-Risk Prostate Cancer Recurrence
2023-11-21
GeneOnline’s Weekly News Highlights: Nov 13-Nov 17
2023-11-20
EVENT
2023-11-30
2023 Healthcare+ EXPO・Taiwan
Taipei , Taiwan
Scroll to Top